Opus Genetics (IRD) Financials

Opus Genetics logo
$3.99 -0.09 (-2.21%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$4.00 +0.01 (+0.25%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Opus Genetics

Annual Income Statements for Opus Genetics

This table shows Opus Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Consolidated Net Income / (Loss)
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Net Income / (Loss) Continuing Operations
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Total Pre-Tax Income
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.97 -58 -50
Total Operating Income
-18 -16 -17 -21 -4.19 -20 -23 18 -11 -62 -39
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.59 40 19 11 14
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.59 40 19 11 14
Operating Revenue
0.00 0.00 0.00 0.00 - 0.00 0.59 40 19 11 14
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
18 16 17 21 4.19 20 23 22 30 73 53
Selling, General & Admin Expense
6.12 6.32 6.64 7.43 1.82 2.82 8.12 7.27 12 18 22
Research & Development Expense
12 10 11 13 2.37 17 15 14 18 55 31
Total Other Income / (Expense), net
3.88 7.11 -7.94 6.17 -1.98 -4.65 -34 -0.02 0.59 4.54 -11
Interest Expense
0.21 0.31 0.55 - 1.41 3.18 0.00 0.01 - 0.00 0.13
Other Income / (Expense), net
3.99 7.30 -7.59 5.91 -0.57 -1.48 -34 -0.01 0.59 4.54 -11
Income Tax Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.01 0.00 0.00
Basic Earnings per Share
($0.79) ($0.43) $0.00 ($5.25) ($2.17) ($5.28) ($3.82) $0.90 ($0.46) ($2.15) ($0.80)
Weighted Average Basic Shares Outstanding
18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 14.85M 19.93M 21.59M 26.72M 62.22M
Diluted Earnings per Share
($0.79) ($0.43) $0.00 ($5.25) ($2.17) ($5.28) ($3.82) $0.87 ($0.46) ($2.15) ($0.80)
Weighted Average Diluted Shares Outstanding
18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 14.85M 20.60M 21.59M 26.72M 62.22M
Weighted Average Basic & Diluted Shares Outstanding
18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 18.99M 20.95M 24.81M 45.48M 71.15M

Quarterly Income Statements for Opus Genetics

This table shows Opus Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Consolidated Net Income / (Loss)
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Net Income / (Loss) Continuing Operations
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Total Pre-Tax Income
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Total Operating Income
-7.71 -8.33 -8.01 -38 -9.93 -8.91 -8.31 -11 -14 -16 -19
Total Gross Profit
1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16 0.76 1.14
Total Revenue
1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16 0.76 1.14
Operating Revenue
1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16 0.76 1.14
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.42 9.44 12 42 14 12 11 15 17 17 20
Selling, General & Admin Expense
4.67 3.35 2.89 7.30 6.35 5.77 4.98 4.89 5.94 6.03 5.89
Research & Development Expense
4.75 6.09 8.98 35 7.95 6.02 6.41 10 11 11 14
Total Other Income / (Expense), net
0.60 0.56 0.48 2.89 1.74 1.49 -9.14 -5.07 -51 8.38 -27
Other Income / (Expense), net
0.60 0.56 0.48 2.89 1.74 1.49 -9.14 -5.01 -51 8.38 -27
Income Tax Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share
($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75) ($0.08) ($0.46)
Weighted Average Basic Shares Outstanding
24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M 95.48M 101.84M
Diluted Earnings per Share
($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75) ($0.14) ($0.46)
Weighted Average Diluted Shares Outstanding
24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M 111.38M 101.84M
Weighted Average Basic & Diluted Shares Outstanding
25.92M 26.20M 31.57M 45.48M 59.66M 59.91M 68.96M 71.15M 81.40M 83.20M 96.65M

Annual Cash Flow Statements for Opus Genetics

This table details how cash moves in and out of Opus Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.37 1.38 -2.68 -0.15 1.09 15 8.14 18 7.87 -20 15
Net Cash From Operating Activities
-17 -13 -15 -19 -3.59 -6.80 -19 14 -1.11 -26 -35
Net Cash From Continuing Operating Activities
-17 -13 -15 -19 -3.59 -6.80 -19 14 -1.11 -26 -35
Net Income / (Loss) Continuing Operations
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Consolidated Net Income / (Loss)
-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Depreciation Expense
0.03 0.03 0.04 0.05 0.00 0.01 0.00 0.00 0.01 0.01 0.05
Non-Cash Adjustments To Reconcile Net Income
-2.64 -3.72 9.21 -4.30 1.10 16 37 -1.58 6.94 28 17
Changes in Operating Assets and Liabilities, net
-0.29 -0.17 0.66 0.11 0.36 1.15 0.18 -2.00 1.93 3.89 -3.19
Net Cash From Investing Activities
9.55 4.48 -9.37 12 -0.03 0.54 -0.10 0.00 0.00 1.21 0.00
Net Cash From Continuing Investing Activities
9.55 4.48 -9.37 12 -0.03 0.54 -0.10 0.00 0.00 1.21 0.00
Divestitures
- - - - 0.00 2.01 - - - - 0.00
Net Cash From Financing Activities
8.17 10 22 6.77 4.70 21 28 3.79 8.98 4.19 50
Net Cash From Continuing Financing Activities
8.17 10 22 6.77 4.70 21 28 3.79 8.98 4.19 50
Repurchase of Common Equity
- - 0.00 -0.10 0.00 -2.28 -1.51 -0.13 -0.28 -0.23 -2.30
Issuance of Debt
- - - - 4.71 2.20 0.65 - - 0.00 1.00
Issuance of Common Equity
7.44 10 17 6.87 - 0.00 28 4.43 9.23 4.50 50
Other Financing Activities, net
0.73 0.00 5.43 - 0.00 21 0.09 0.03 0.03 -0.08 1.02
Cash Interest Paid
- - - - 0.00 0.00 0.00 0.01 0.00 0.00 0.00
Cash Income Taxes Paid
- - - - 0.00 0.00 0.00 0.00 0.34 0.00 0.00

Quarterly Cash Flow Statements for Opus Genetics

This table details how cash moves in and out of Opus Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-3.34 -5.75 -4.78 -6.31 11 -9.36 -1.61 14 15 29 0.16
Net Cash From Operating Activities
-5.72 -7.29 -5.13 -7.44 -8.99 -10 -6.16 -9.83 -13 -12 -14
Net Cash From Continuing Operating Activities
-5.72 -7.29 -5.13 -7.44 -8.99 -10 -6.16 -9.83 -13 -12 -14
Net Income / (Loss) Continuing Operations
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Consolidated Net Income / (Loss)
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66 -8.10 -46
Depreciation Expense
0.00 - - 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income
1.21 1.05 0.26 26 0.02 0.44 10 6.80 53 -4.01 30
Changes in Operating Assets and Liabilities, net
0.18 -0.58 2.14 2.15 -0.83 -3.31 1.06 -0.12 -0.29 0.43 2.13
Net Cash From Investing Activities
0.00 - - 1.21 0.00 - - - 0.00 - -0.19
Net Cash From Continuing Investing Activities
0.00 - - 1.21 0.00 - - - 0.00 - -0.19
Net Cash From Financing Activities
2.38 1.54 0.35 -0.08 20 0.91 4.54 24 28 41 14
Net Cash From Continuing Financing Activities
2.38 1.54 0.35 -0.08 20 0.91 4.54 24 28 41 14
Other Financing Activities, net
-0.04 - - -0.04 -0.03 - 0.02 1.03 0.71 42 14
Cash Interest Paid
0.00 - - - 0.00 - - - 0.00 0.28 0.37

Annual Balance Sheets for Opus Genetics

This table presents Opus Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
25 21 28 16 1.78 18 26 49 54 37 50
Total Current Assets
25 21 28 16 1.76 18 26 49 54 37 50
Cash & Equivalents
10 12 8.90 8.74 1.54 16 25 43 51 30 45
Accounts Receivable
- - - - - - 0.00 1.30 0.93 3.56 2.00
Prepaid Expenses
1.22 0.61 1.30 1.17 0.15 1.27 1.31 1.45 1.10 0.52 1.79
Other Current Assets
- - - - 0.08 - 0.00 3.55 1.41 2.21 1.17
Plant, Property, & Equipment, net
0.11 0.09 0.12 0.11 0.02 0.01 0.01 0.01 0.00 0.25 0.20
Total Noncurrent Assets
0.03 0.03 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
0.03 0.03 0.03 0.03 - - - - - - 0.00
Total Liabilities & Shareholders' Equity
25 21 28 16 1.78 18 26 49 54 37 50
Total Liabilities
6.03 3.99 12 5.48 9.34 31 3.86 2.75 4.04 11 35
Total Current Liabilities
5.40 3.46 11 3.15 9.34 3.19 3.86 2.75 4.04 11 7.78
Accounts Payable
2.66 1.88 3.23 3.15 0.34 1.21 1.58 1.07 2.15 3.15 3.29
Accrued Expenses
- - - - 0.62 1.97 1.73 1.68 1.82 8.15 4.49
Total Noncurrent Liabilities
0.63 0.53 0.43 2.33 0.00 28 0.00 0.00 0.00 0.00 27
Long-Term Debt
- - - - - - - - - 0.00 1.13
Other Noncurrent Operating Liabilities
0.53 0.45 0.38 2.31 0.00 28 0.00 - - 0.00 26
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
19 17 17 11 -7.56 -13 22 46 50 6.72 15
Total Preferred & Common Equity
19 17 17 11 -7.56 -13 22 46 50 6.72 15
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
19 17 17 11 -7.56 -13 22 46 50 6.72 15
Common Stock
125 132 157 165 0.50 19 112 118 131 146 204
Retained Earnings
-106 -115 -140 -155 -8.06 -33 -89 -71 -81 -139 -189
Accumulated Other Comprehensive Income / (Loss)
-0.02 -0.01 -0.06 -0.02 - - - - - - 0.00

Quarterly Balance Sheets for Opus Genetics

This table presents Opus Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
54 52 45 40 48 39 36 67 93 95
Total Current Assets
54 52 45 40 48 38 36 67 93 95
Cash & Equivalents
42 47 41 37 42 32 31 60 89 89
Accounts Receivable
10 1.92 1.36 1.86 3.08 3.40 2.92 1.73 1.04 1.01
Prepaid Expenses
0.48 1.56 1.11 0.43 1.38 1.43 0.82 3.93 2.43 4.25
Other Current Assets
1.21 1.19 0.95 1.47 1.68 1.18 1.36 0.98 0.42 0.63
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.24 0.23 0.21 0.19 0.17 0.34
Total Noncurrent Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.10
Other Noncurrent Operating Assets
- - - - - - - - 0.10 0.10
Total Liabilities & Shareholders' Equity
54 52 45 40 48 39 36 67 93 95
Total Liabilities
3.91 5.79 4.20 6.09 24 21 30 88 106 57
Total Current Liabilities
3.91 5.79 4.20 6.09 24 20 29 9.34 7.61 9.83
Accounts Payable
1.89 2.06 0.63 0.84 2.43 1.47 2.40 4.42 1.88 3.73
Accrued Expenses
1.93 3.65 3.49 5.17 9.11 6.93 5.37 4.92 5.72 6.11
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 1.00 1.07 79 98 47
Long-Term Debt
- - - - - 1.00 1.07 1.20 36 36
Other Noncurrent Operating Liabilities
- - - - - - - 77 62 11
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
50 46 41 34 5.07 17 5.97 -46 -13 38
Total Preferred & Common Equity
50 46 41 34 5.07 17 5.97 -46 -13 38
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
50 46 41 34 5.07 17 5.97 -46 -13 38
Common Stock
127 135 137 138 152 172 178 208 249 346
Retained Earnings
-77 -89 -96 -104 -147 -155 -172 -254 -262 -309
Accumulated Other Comprehensive Income / (Loss)
- - - - - - - - - 1.11

Annual Metrics And Ratios for Opus Genetics

This table displays calculated financial ratios and metrics derived from Opus Genetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
180,747,118.00 237,368,785.00 31,725,114.00 37,521,170.00 4,019,141.00 4,483,198.00 17,300,481.00 20,807,015.00 22,637,600.00 31,568,457.00 68,964,208.00
DEI Adjusted Shares Outstanding
376,556.00 494,518.00 660,940.00 781,691.00 1,004,785.00 1,120,800.00 17,300,481.00 20,807,015.00 22,637,600.00 31,568,457.00 68,964,208.00
DEI Earnings Per Adjusted Shares Outstanding
-38.20 -18.82 -38.27 -18.38 -6.14 -21.97 -3.28 0.86 -0.44 -1.82 -0.72
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,665.70% -52.20% -42.30% 29.15%
EBITDA Growth
23.32% 36.07% -172.74% 40.22% 75.57% -462.69% -176.62% 132.13% -154.72% -477.07% 14.10%
EBIT Growth
22.62% 36.17% -173.78% 41.39% 67.45% -350.53% -164.36% 132.13% -154.77% -476.82% 14.03%
NOPAT Growth
-37.64% 10.13% -5.74% -18.34% 79.58% -376.22% -13.71% 212.69% -141.28% -487.66% 37.82%
Net Income Growth
22.34% 35.30% -171.77% 43.20% 57.07% -299.09% -130.27% 131.55% -155.83% -476.13% 13.80%
EPS Growth
22.34% 35.30% 100.00% 43.20% 57.07% -143.32% 27.65% 122.77% -152.87% -367.39% 62.79%
Operating Cash Flow Growth
-57.16% 23.77% -16.58% -22.17% 80.93% -89.17% -184.98% 173.90% -107.77% -2,200.00% -37.84%
Free Cash Flow Firm Growth
-49.41% 9.43% 58.57% -279.49% 81.91% 439.65% -451.30% 128.24% -126.11% -1,117.61% 91.96%
Invested Capital Growth
23.76% 30.16% -208.94% 58.63% 17.61% -770.73% 93.33% 278.42% -117.15% -679.67% -501.64%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -66.70% 31.15% -2.99%
EBITDA Q/Q Growth
-3.05% 18.64% -13.01% 1.94% 64.39% -1,373.67% 14.17% 181.50% -134.27% -111.55% 27.43%
EBIT Q/Q Growth
-3.06% 18.75% -13.07% 1.83% 53.31% -510.11% 14.17% 181.47% -134.30% -111.56% 27.41%
NOPAT Q/Q Growth
-2.90% 2.66% -5.98% -0.33% 70.42% -2,044.31% 25.75% 215.60% -125.72% -110.61% 40.78%
Net Income Q/Q Growth
-4.67% 20.00% -13.80% 3.21% 37.58% -360.83% 17.91% 179.98% -134.73% -111.58% 27.29%
EPS Q/Q Growth
-4.67% 20.00% 100.00% 3.21% 37.58% -269.23% 6.37% 179.82% -134.33% -100.93% 57.45%
Operating Cash Flow Q/Q Growth
-9.43% 18.06% -16.74% -5.11% 72.75% -368.38% -7.12% 171.13% -104.81% -88.20% -7.29%
Free Cash Flow Firm Q/Q Growth
9.30% -17.43% 32.81% -24.72% 73.64% 2,900.99% -101.66% 179.85% -117.22% -278.82% 86.92%
Invested Capital Q/Q Growth
-24.34% 28.76% -24.49% 32.35% -58.91% -1,162.59% 3.58% 271.04% -107.70% -103.68% -20.33%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,624.28% 45.71% -52.33% -523.31% -348.05%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,854.84% 45.74% -55.45% -564.72% -271.90%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,624.96% 45.70% -52.36% -523.40% -348.42%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,625.30% 44.89% -52.42% -523.40% -349.33%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.27% 100.12% 100.00% 100.00%
Interest Burden Percent
100.76% 102.13% 101.39% 98.26% 129.60% 114.81% 100.00% 99.95% 100.00% 100.00% 100.26%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.73% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,291.82% -501.98% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,291.89% -496.41% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,239.57% 481.20% 0.00% 0.00%
Return on Equity (ROE)
-63.43% -51.95% -149.55% -105.14% -410.87% 234.18% -1,295.10% 52.26% -20.77% -152.46% -242.41%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 347.63% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -259.11% 48.52% -19.38% -126.71% -113.57%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -259.11% 47.66% -19.40% -126.71% -113.86%
Return on Common Equity (ROCE)
-63.43% -51.95% -149.55% -105.14% -410.87% 234.18% -1,295.10% 52.26% -20.77% -114.39% -130.77%
Return on Equity Simple (ROE_SIMPLE)
-76.61% -54.56% -150.84% -136.03% 81.60% 182.82% -255.12% 38.69% -20.01% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -11 -12 -14 -2.94 -14 -16 18 -7.39 -43 -27
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,698.39% 44.95% -38.82% -395.30% -190.33%
Net Nonoperating Expense Percent (NNEP)
-5.70% 9.97% -55.77% 0.04% -61.04% -173.48% -200.91% -0.07% -5.56% -34.84% -60.77%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -14.82% -646.22% -163.98%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,378.78% 18.24% 62.78% 165.71% 154.85%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,576.06% 36.02% 92.67% 499.01% 217.05%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,954.84% 54.26% 155.45% 664.72% 371.90%
Earnings before Interest and Taxes (EBIT)
-14 -9.11 -25 -15 -4.76 -21 -57 18 -9.97 -58 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -9.15 -25 -15 -3.64 -20 -57 18 -9.97 -58 -49
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.49 1.97 3.82 3.30 0.00 0.00 2.90 1.59 1.37 5.59 9.03
Price to Tangible Book Value (P/TBV)
3.49 1.97 3.82 3.30 0.00 0.00 2.90 1.59 1.37 5.59 9.03
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 109.56 1.84 3.58 3.42 9.76
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.11 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.35% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.65 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 68.45 0.77 0.93 2.37 6.67
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.72 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.15 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.49 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 -0.75 0.00 0.02 0.00 0.00 0.00 0.07
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Financial Leverage
-1.24 -1.22 -1.39 -1.52 -3.53 0.58 -4.64 -0.98 -0.97 -1.07 -1.82
Leverage Ratio
1.29 1.28 1.46 1.62 5.94 -0.93 5.00 1.10 1.07 1.20 2.13
Compound Leverage Factor
1.30 1.31 1.48 1.59 7.69 -1.06 5.00 1.10 1.07 1.20 2.13
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% -299.37% 0.00% 2.36% 0.00% 0.00% 0.00% 6.85%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% -299.37% 0.00% 2.36% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.85%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 73.70% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 399.37% 100.00% 97.64% 100.00% 100.00% 26.30% 93.15%
Debt to EBITDA
0.00 0.00 0.00 0.00 -1.56 0.00 -0.01 0.00 0.00 0.00 -0.02
Net Debt to EBITDA
0.00 0.00 0.00 0.00 -1.13 0.00 0.43 0.00 0.00 0.00 0.89
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Debt to NOPAT
0.00 0.00 0.00 0.00 -1.93 0.00 -0.03 0.00 0.00 0.00 -0.04
Net Debt to NOPAT
0.00 0.00 0.00 0.00 -1.41 0.00 1.52 0.00 0.00 0.00 1.63
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04
Altman Z-Score
-0.41 -3.01 -5.79 -11.73 -19.73 -5.47 -0.88 17.14 8.85 -7.31 -4.83
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.97% 46.05%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.57 6.05 2.54 5.04 0.19 5.55 6.76 17.79 13.35 3.24 6.43
Quick Ratio
4.34 5.88 2.42 4.67 0.16 5.15 6.42 15.98 12.73 3.00 6.05
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-14 -13 -5.34 -20 -3.67 12 -44 12 -3.23 -39 -3.16
Operating Cash Flow to CapEx
-27,851.35% -152,632.14% -20,514.12% -48,028.34% -14,372.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-67.44 -41.19 -9.67 0.00 -2.60 3.92 -21,883.25 1,373.51 0.00 0.00 -24.51
Operating Cash Flow to Interest Expense
-82.19 -42.25 -27.90 0.00 -2.55 -2.14 -9,685.00 1,590.44 0.00 0.00 -273.28
Operating Cash Flow Less CapEx to Interest Expense
-82.49 -42.27 -28.04 0.00 -2.57 -2.14 -9,685.00 1,590.44 0.00 0.00 -273.28
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.03 1.06 0.37 0.24 0.33
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.13 4.90 5.11
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 49.08 4,981.25 0.00 0.00 62.95
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.31 74.53 71.45
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.31 74.53 71.45
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-4.66 -3.26 -10 -4.16 -3.43 -30 -1.99 3.56 -0.61 -4.76 -29
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 -0.04 50.99 12.93 -4.10 -0.85
Increase / (Decrease) in Invested Capital
1.45 1.41 -6.81 5.90 0.73 -26 28 5.55 -4.17 -4.15 -24
Enterprise Value (EV)
42 13 37 20 12 -9.13 40 31 18 26 95
Market Capitalization
66 34 64 35 7.68 7.27 65 73 68 38 139
Book Value per Share
$0.10 $0.07 $0.53 $0.28 ($1.88) ($3.00) $1.28 $2.22 $2.20 $0.21 $0.22
Tangible Book Value per Share
$0.10 $0.07 $0.53 $0.28 ($1.88) ($3.00) $1.28 $2.22 $2.20 $0.21 $0.22
Total Capital
19 17 17 11 -1.89 -13 23 46 50 26 16
Total Debt
0.00 0.00 0.00 0.00 5.67 0.00 0.54 0.00 0.00 0.00 1.13
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.13
Net Debt
-23 -20 -27 -15 4.13 -16 -24 -43 -51 -30 -44
Capital Expenditures (CapEx)
0.06 0.01 0.08 0.04 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.18 -2.85 -9.78 -1.98 -3.45 -1.92 -2.00 3.55 -0.61 -5.01 -2.83
Debt-free Net Working Capital (DFNWC)
19 17 17 13 -1.92 14 23 46 50 25 42
Net Working Capital (NWC)
19 17 17 13 -7.58 14 22 46 50 25 42
Net Nonoperating Expense (NNE)
1.60 -2.18 13 -0.01 3.23 11 41 0.02 2.59 14 23
Net Nonoperating Obligations (NNO)
-23 -20 -27 -15 4.13 -16 -24 -43 -51 -30 -44
Total Depreciation and Amortization (D&A)
-0.03 -0.03 0.01 -0.29 1.12 0.95 0.00 0.00 0.01 0.01 0.05
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -340.07% 8.91% -3.20% -45.56% -19.92%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,862.48% 116.02% 261.99% 230.30% 297.71%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,771.14% 116.02% 261.99% 230.30% 297.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) ($3.82) $0.90 ($0.46) ($2.15) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 0.00 1.00M 10.93M 14.85M 19.93M 21.59M 26.72M 62.22M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) ($3.82) $0.87 ($0.46) ($2.15) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 0.00 1.00M 10.93M 14.85M 20.60M 21.59M 26.72M 62.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 0.00 990.04K 4.66M 18.99M 20.95M 24.81M 45.48M 71.15M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -11 -12 -14 -2.94 -14 -16 18 -7.39 -43 -27
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,698.39% 44.95% -38.82% -395.30% -190.33%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,625.30% 45.68% -52.36% -523.40% -349.33%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-67.63 -29.11 -45.15 0.00 -3.38 -6.75 -28,345.50 2,023.56 0.00 0.00 -383.43
NOPAT to Interest Expense
-60.56 -36.70 -21.98 0.00 -2.08 -4.40 -7,946.75 1,990.07 0.00 0.00 -209.45
EBIT Less CapEx to Interest Expense
-67.92 -29.13 -45.28 0.00 -3.40 -6.75 -28,345.50 2,023.56 0.00 0.00 -383.43
NOPAT Less CapEx to Interest Expense
-60.85 -36.72 -22.12 0.00 -2.10 -4.40 -7,946.75 1,990.07 0.00 0.00 -209.45
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -0.70% 0.00% -9.24% -2.67% 0.73% -2.78% -0.40% -4.64%

Quarterly Metrics And Ratios for Opus Genetics

This table displays calculated financial ratios and metrics derived from Opus Genetics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
24,813,370.00 25,924,158.00 26,198,444.00 31,568,457.00 45,483,823.00 59,661,197.00 59,908,055.00 68,964,208.00 71,149,045.00 81,395,539.00 83,195,823.00
DEI Adjusted Shares Outstanding
24,813,370.00 25,924,158.00 26,198,444.00 31,568,457.00 45,483,823.00 59,661,197.00 59,908,055.00 68,964,208.00 71,149,045.00 81,395,539.00 83,195,823.00
DEI Earnings Per Adjusted Shares Outstanding
-0.29 -0.30 -0.29 -1.11 -0.18 -0.12 -0.29 -0.24 -0.92 -0.10 -0.56
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-2.17% -69.73% -67.60% 154.41% 155.41% 159.17% -20.38% -10.16% -50.64% -73.80% -63.07%
EBITDA Growth
-22.73% -56.55% -234.97% -632.69% -15.13% 4.62% -130.84% 53.17% -700.06% -9.15% -166.46%
EBIT Growth
-22.71% -56.52% -235.00% -632.44% -15.31% 4.44% -131.01% 53.15% -698.95% -9.14% -166.39%
NOPAT Growth
-25.72% -54.54% -188.01% -600.48% -28.81% -6.94% -3.77% 69.88% -44.67% -85.04% -131.58%
Net Income Growth
-22.71% -56.52% -235.34% -632.74% -15.31% 4.44% -131.92% 52.97% -699.79% -9.14% -166.39%
EPS Growth
-3.57% -25.00% -216.00% -568.42% 17.24% 60.00% 13.79% 85.04% -212.50% -16.67% -84.00%
Operating Cash Flow Growth
-56.77% -837.31% -70.83% -263.54% -57.35% -40.83% -20.02% -32.20% -41.51% -16.37% -127.97%
Free Cash Flow Firm Growth
75.71% -82.15% 228.09% -6,245.56% 579.71% 194.52% 236.09% 170.48% 428.93% 477.52% -244.56%
Invested Capital Growth
-149.51% 66.10% -129.48% -679.67% -1,511.99% -1,693.83% -918.42% -501.64% -346.72% -370.01% 38.34%
Revenue Q/Q Growth
1.18% -35.01% 247.75% 11.25% 1.58% -34.05% 6.84% 25.53% -44.19% -65.00% 50.60%
EBITDA Q/Q Growth
-48.23% -9.27% 3.08% -366.72% 76.71% 9.47% -134.58% 5.32% -297.91% 87.65% -474.88%
EBIT Q/Q Growth
-48.13% -9.27% 3.08% -366.85% 76.68% 9.45% -134.31% 5.31% -297.68% 87.63% -474.15%
NOPAT Q/Q Growth
-41.98% -8.04% 3.83% -374.83% 73.89% 10.30% 6.68% -37.81% -25.42% -14.73% -16.79%
Net Income Q/Q Growth
-48.20% -9.27% 3.08% -366.85% 76.68% 9.45% -135.23% 5.33% -296.63% 87.64% -474.15%
EPS Q/Q Growth
-52.63% -3.45% 3.33% -337.93% 81.10% 50.00% -108.33% 24.00% -294.74% 81.33% -228.57%
Operating Cash Flow Q/Q Growth
-225.68% -27.57% 29.65% -44.99% -20.92% -14.18% 40.04% -59.70% -29.43% 6.11% -17.46%
Free Cash Flow Firm Q/Q Growth
-659.64% -258.97% 163.29% -583.35% 143.68% -29.27% 125.05% 1.37% 227.82% -22.78% -156.33%
Invested Capital Q/Q Growth
-81.80% 29.85% -200.13% -103.68% -275.88% 21.93% -70.39% -20.33% -179.10% 17.86% 77.65%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-415.31% -698.29% -194.62% -816.48% -187.21% -256.97% -564.24% -425.59% -3,034.45% -1,070.73% -4,087.34%
Operating Margin
-450.50% -748.92% -207.11% -883.98% -227.21% -309.02% -269.93% -296.33% -665.92% -2,182.78% -1,692.79%
EBIT Margin
-415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -564.66% -425.93% -3,035.05% -1,072.58% -4,089.27%
Profit (Net Income) Margin
-415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -566.87% -427.50% -3,038.25% -1,072.58% -4,089.27%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.39% 100.37% 100.11% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-10,601.37% 0.00% -435.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-10,597.40% 0.00% -430.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
10,460.12% 0.00% 401.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-141.25% -36.01% -33.27% -152.46% -167.55% -200.57% -338.75% -242.41% -7,594.60% -4,796.52% -615.57%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-162.38% -260.17% -34.49% -197.72% -51.19% -95.10% -215.99% -138.83% -632.76% -160.62% -492.52%
Return on Assets (ROA)
-162.38% -260.17% -34.49% -197.72% -51.19% -95.10% -216.83% -139.35% -633.42% -160.62% -492.52%
Return on Common Equity (ROCE)
-141.25% -36.01% -33.27% -114.39% -122.43% -200.57% -338.75% -130.77% 109,935.64% -4,796.52% -615.57%
Return on Equity Simple (ROE_SIMPLE)
-24.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-5.40 -5.83 -5.61 -27 -6.95 -6.23 -5.82 -8.02 -10 -12 -13
NOPAT Margin
-315.35% -524.24% -144.98% -618.79% -159.05% -216.32% -188.95% -207.43% -466.15% -1,527.95% -1,184.95%
Net Nonoperating Expense Percent (NNEP)
-3.97% -4.75% -4.86% -21.07% -2.80% -3.26% -35.06% -22.90% -110.35% 8.18% -79.73%
Return On Investment Capital (ROIC_SIMPLE)
-11.72% -14.35% -16.34% -395.90% -137.01% -33.75% -82.70% -48.66% 22.53% -49.69% -18.13%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
272.94% 301.62% 74.84% 169.62% 145.22% 200.07% 161.77% 126.52% 275.57% 798.41% 518.03%
R&D to Revenue
277.56% 547.30% 232.27% 814.37% 181.99% 208.95% 208.15% 269.81% 490.36% 1,484.37% 1,274.76%
Operating Expenses to Revenue
550.50% 848.92% 307.11% 983.98% 327.21% 409.02% 369.93% 396.33% 765.92% 2,282.78% 1,792.79%
Earnings before Interest and Taxes (EBIT)
-7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -16 -65 -8.10 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.11 -7.77 -7.53 -35 -8.18 -7.41 -17 -16 -65 -8.08 -46
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.08 0.98 1.00 5.59 8.80 3.22 16.57 9.03 0.00 0.00 10.48
Price to Tangible Book Value (P/TBV)
1.08 0.98 1.00 5.59 8.80 3.22 16.57 9.03 0.00 0.00 10.48
Price to Revenue (P/Rev)
2.62 2.41 4.10 3.42 3.27 3.64 6.76 9.76 27.02 33.94 50.88
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.14 0.00 0.00 2.37 1.59 1.61 4.72 6.67 24.18 28.60 44.17
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.09 17.39 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.06 0.18 0.07 -0.06 -2.79 0.93
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.06 0.18 0.07 -0.06 -2.79 0.93
Financial Leverage
-0.99 -1.04 -0.93 -1.07 -1.27 -1.25 -1.65 -1.82 -35.71 -18.73 -1.87
Leverage Ratio
1.11 1.13 1.12 1.20 1.43 1.44 1.90 2.13 40.82 29.34 2.96
Compound Leverage Factor
1.11 1.13 1.12 1.20 1.43 1.44 1.91 2.14 40.86 29.34 2.96
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 5.41% 15.18% 6.85% -6.02% 155.93% 48.28%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 5.41% 15.18% 6.85% -6.02% 155.93% 48.28%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 73.70% 78.79% 0.00% 0.00% 0.00% -124.29% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 26.30% 21.21% 94.59% 84.82% 93.15% 230.31% -55.93% 51.72%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.01 -0.34 -0.26
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.54 0.44 0.89 0.55 0.49 0.39
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.01 -0.34 -0.26
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.04 -0.04 -1.02 -0.83
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.69 0.65 1.63 1.95 1.49 1.23
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.04 -0.04 -1.02 -0.83
Altman Z-Score
3.76 3.54 0.39 -5.31 -2.86 -3.68 -5.66 -2.66 -5.14 -1.14 -0.74
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 24.97% 26.93% 0.00% 0.00% 46.05% 1,547.55% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
8.96 10.68 6.63 3.24 1.98 1.90 1.23 6.43 7.13 12.19 9.65
Quick Ratio
8.48 10.19 6.32 3.00 1.85 1.77 1.16 6.05 6.60 11.82 9.15
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.05 -7.35 4.65 -22 9.82 6.94 16 16 52 40 -23
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 229.81 0.00 752.60 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -90.54 0.00 -184.45 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -90.54 0.00 -184.45 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.39 0.37 0.18 0.24 0.27 0.37 0.38 0.33 0.21 0.15 0.12
Accounts Receivable Turnover
7.99 22.03 1.40 4.90 5.46 6.48 6.13 5.11 4.98 4.44 4.04
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 62.95 56.39 49.53 28.73
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
45.68 16.56 261.07 74.53 66.90 56.30 59.53 71.45 73.27 82.21 90.42
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
45.68 16.56 261.07 74.53 66.90 56.30 59.53 71.45 73.27 82.21 90.42
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.11 -0.78 -2.34 -4.76 -18 -14 -24 -29 -80 -66 -15
Invested Capital Turnover
33.62 -10.71 3.00 -4.10 -1.44 -2.09 -1.12 -0.85 -0.25 -0.25 -0.41
Increase / (Decrease) in Invested Capital
-3.35 1.52 -10 -4.15 -17 -13 -21 -24 -62 -52 9.12
Enterprise Value (EV)
2.71 -1.75 -2.32 26 22 25 69 95 290 282 350
Market Capitalization
50 40 34 38 45 56 99 139 324 335 403
Book Value per Share
$1.86 $1.57 $1.31 $0.21 $0.16 $0.29 $0.10 $0.22 ($0.64) ($0.16) $0.46
Tangible Book Value per Share
$1.86 $1.57 $1.31 $0.21 $0.16 $0.29 $0.10 $0.22 ($0.64) ($0.16) $0.46
Total Capital
46 41 34 26 24 18 7.04 16 -20 23 74
Total Debt
0.00 0.00 0.00 0.00 0.00 1.00 1.07 1.13 1.20 36 36
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 1.00 1.07 1.13 1.20 36 36
Net Debt
-47 -41 -37 -30 -42 -31 -30 -44 -59 -53 -53
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.11 -0.78 -2.34 -5.01 -18 -14 -24 -2.83 -2.70 -3.72 -3.95
Debt-free Net Working Capital (DFNWC)
46 41 34 25 24 18 6.82 42 57 85 85
Net Working Capital (NWC)
46 41 34 25 24 18 6.82 42 57 85 85
Net Nonoperating Expense (NNE)
1.71 1.94 1.92 8.51 1.24 1.19 12 8.51 55 -3.44 33
Net Nonoperating Obligations (NNO)
-47 -41 -37 -30 -42 -31 -30 -44 -59 -53 -53
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02
Debt-free, Cash-free Net Working Capital to Revenue
-5.83% -4.73% -27.86% -45.56% -132.71% -91.97% -163.96% -19.92% -22.52% -37.75% -49.91%
Debt-free Net Working Capital to Revenue
242.27% 247.04% 409.26% 230.30% 173.45% 118.33% 46.63% 297.71% 477.85% 863.34% 1,074.35%
Net Working Capital to Revenue
242.27% 247.04% 409.26% 230.30% 173.45% 118.33% 46.63% 297.71% 477.85% 863.34% 1,074.35%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75) ($0.08) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding
24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M 95.48M 101.84M
Adjusted Diluted Earnings per Share
($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75) ($0.14) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding
24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M 111.38M 101.84M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.92M 26.20M 31.57M 45.48M 59.66M 59.91M 68.96M 71.15M 81.40M 83.20M 96.65M
Normalized Net Operating Profit after Tax (NOPAT)
-5.40 -5.83 -5.61 -27 -6.95 -6.23 -5.82 -8.02 -10 -12 -13
Normalized NOPAT Margin
-315.35% -524.24% -144.98% -618.79% -159.05% -216.32% -188.95% -207.43% -466.15% -1,527.95% -1,184.95%
Pre Tax Income Margin
-415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -566.87% -427.50% -3,038.25% -1,072.58% -4,089.27%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -255.68 0.00 -948.78 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -85.55 0.00 -145.72 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -255.68 0.00 -948.78 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -85.55 0.00 -145.72 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-3.00% -2.56% -1.32% -0.40% -2.70% -2.84% -3.30% -4.64% -1.17% -1.19% -0.43%

Financials Breakdown Chart

Key Financial Trends

Opus Genetics’ latest statements show improving liquidity but continued dependence on external financing. Revenue remains modest relative to operating costs, and the company has generated recurring operating losses and negative operating cash flow throughout the reported periods. The balance sheet has strengthened in cash terms, although liabilities now exceed assets and shareholders’ equity is negative.

  • Cash increased substantially: Cash and equivalents rose to $88.8 million at June 30, 2026, up from $60.0 million in Q1 2026 and $30.8 million in Q3 2025.
  • Strong short-term liquidity: Total current assets of $92.7 million compared with current liabilities of $7.6 million, producing a current ratio of roughly 12.2.
  • Quarterly net loss improved: The Q2 2026 net loss was $8.1 million, substantially better than the $65.5 million loss in Q1 2026. The improvement was largely associated with a swing in other income from a $51.1 million expense in Q1 to $8.4 million of income in Q2.
  • Revenue exceeded the prior quarter: Q2 2026 revenue was $755,000, down from earlier periods but higher than no revenue would have been; the company continues to report revenue with no cost of revenue, resulting in reported gross profit equal to revenue.
  • Research spending remains elevated: Research and development expense was $11.2 million in Q2 2026, up from $6.1 million in Q2 2024 and $6.4 million in Q3 2025. This may support pipeline development, but it also contributes materially to cash burn.
  • Financing has been the primary source of liquidity: Opus Genetics generated $40.9 million of financing cash flow in Q2 2026 after raising $27.6 million in Q1 2026 and $24.1 million in Q4 2025. The cash balance therefore reflects continued access to financing rather than internally generated cash.
  • Operating cash flow remains negative: The company used $11.9 million of cash in operating activities during Q2 2026, following $12.7 million in Q1 2026 and $9.8 million in Q4 2025. Operating cash flow has been negative in nearly every reported quarter in the data set.
  • Revenue has deteriorated over the longer term: Quarterly revenue declined from $11.9 million in Q3 2023 to $3.9 million in Q4 2024, $2.2 million in Q1 2026 and $755,000 in Q2 2026. The company has not yet demonstrated a sustained revenue-growth trend.
  • Operating losses are persistent: Q2 2026 operating income was negative $16.5 million, compared with negative $14.4 million in Q1 2026 and negative $11.5 million in Q4 2025. Operating expenses continue to greatly exceed revenue.
  • Balance-sheet solvency has weakened: Total liabilities reached $106.0 million at June 30, 2026, exceeding total assets of $93.0 million. Common equity was negative $13.0 million, while long-term debt increased to $36.2 million and other noncurrent operating liabilities totaled $62.1 million.
  • Share dilution is a major risk: Weighted-average basic shares increased from approximately 21.6 million in Q4 2023 to 95.5 million in Q2 2026. Additional equity financing could provide liquidity but may further reduce existing shareholders’ ownership percentage.

Overall, the most favorable development is the company’s $88.8 million cash balance and improved Q2 net loss. However, the core operating trend remains challenging: revenue is shrinking, operating cash flow is negative, liabilities exceed assets, and the business continues to rely on financing to fund research and operations. Investors should focus on whether revenue growth and internally generated cash flow improve before the current cash reserves are depleted.

11/21/26 06:57 PM ETAI Generated. May Contain Errors.

Opus Genetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Opus Genetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Opus Genetics' net income appears to be on a downward trend, with a most recent value of -$49.59 million in 2025, falling from -$14.38 million in 2015. The previous period was -$57.53 million in 2024. Find out what analysts predict for Opus Genetics in the coming months.

Opus Genetics' total operating income in 2025 was -$38.60 million, based on the following breakdown:
  • Total Gross Profit: $14.20 million
  • Total Operating Expenses: $52.80 million

Over the last 10 years, Opus Genetics' total revenue changed from $0.00 in 2015 to $14.20 million in 2025, a change of 1,419,600,000.0%.

In the past 12 quarters, Opus Genetics' cash and equivalents has ranged from $30.82 million in Q3 2025 to $88.97 million in Q3 2026, and is currently $88.97 million as of their latest financial filing in Q3 2026.

Opus Genetics had total debt of $1.13 million at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Opus Genetics' book value per share changed from 0.10 in 2015 to 0.22 in 2025, a change of 114.2%.



Financial statements for NASDAQ:IRD last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners